Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from CD20 bispecific T-cell engager depletes B-cell progenitors preventing EBV-associated lymphomagenesis in humanized mice. Local targets link to admitted publications; unresolved targets remain external evidence.
Gammaherpesviruses and lymphoproliferative disorders
10.1146/annurev-pathol-012513-104656 · 2014 · External reference
Epstein–Barr virus and cancer
10.1146/annurev-pathmechdis-012418-013023 · 2019 · External reference
Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis
10.1016/s2214-109x(19)30488-7 · 2020 · External reference
The global landscape of EBV-associated tumors
10.3389/fonc.2019.00713 · 2019 · External reference
Selective transformation of B lymphocytes by E.B. virus
10.1016/s0140-6736(73)93286-8 · 1973 · External reference
EBV persistence in memory B cells in vivo
10.1016/s1074-7613(00)80622-6 · 1998 · External reference
Epstein Barr virus volume 1, one herpes virus: many diseases
2015 · External reference
How EBV infects: the tropism and underlying molecular mechanism for viral infection
10.3390/v14112372 · 2022 · External reference
Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis
10.1016/0092-8674(87)90216-9 · 1987 · External reference
Human complement receptor type 1/CD35 is an Epstein-Barr virus receptor
10.1016/j.celrep.2013.01.023 · 2013 · External reference
Fusion of Epstein-Barr virus with epithelial cells can be triggered by αvβ5 in addition to αvβ6 and αvβ8, and integrin binding triggers a conformational change in glycoproteins gHgL
10.1128/jvi.05580-11 · 2011 · External reference
Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells
10.1038/ncomms7240 · 2015 · External reference
R9AP is a common receptor for EBV infection in epithelial cells and B cells
10.1038/s41586-025-09166-w · 2025 · External reference
Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes
10.1128/jvi.71.6.4657-4662.1997 · 1997 · External reference
Latency and lytic replication in Epstein–Barr virus-associated oncogenesis
10.1038/s41579-019-0249-7 · 2019 · External reference
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial
10.1016/s2352-3026(23)00279-x · 2023 · External reference
Rituximab for posttransplant lymphoproliferative disorder – therapeutic, preemptive, or prophylactic?
10.1038/s41409-023-02155-5 · 2024 · External reference
Rituximab in the treatment of EBV-positive low grade B-cell lymphoma
2013 · External reference
Management of Epstein–Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation
10.1177/2040620720910964 · 2020 · External reference
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
10.1038/s41409-023-02127-9 · 2024 · External reference
T-cell-engaging bispecific antibodies in cancer
10.1016/s0140-6736(23)00521-4 · 2023 · External reference
Multi-specific antibodies for cancer immunotherapy
10.1007/s40259-014-0091-4 · 2014 · External reference
T cells armed with anti-CD3 × anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro
10.1016/j.exphem.2005.01.007 · 2005 · External reference
‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization
10.1093/protein/9.7.617 · 1996 · External reference
Cyclone: an accessible pipeline to analyze, evaluate, and optimize multiparametric cytometry data
10.3389/fimmu.2023.1167241 · 2023 · External reference
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components
10.1084/jem.20081720 · 2009 · External reference
EBV persistence without its EBNA3A and 3C oncogenes in vivo
10.1371/journal.ppat.1007039 · 2018 · External reference
Human B cell memory
10.1016/j.coi.2009.05.019 · 2009 · External reference
Cytokine release syndrome
10.1186/s40425-018-0343-9 · 2018 · External reference
Dissecting the mechanisms underlying the cytokine release syndrome (CRS) mediated by T cell bispecific antibodies
10.1158/1078-0432.ccr-22-3667 · 2023 · External reference
CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo
10.1371/journal.ppat.1007748 · 2019 · External reference
CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity
10.1126/scitranslmed.aax8861 · 2019 · External reference
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma
10.1182/bloodadvances.2021005954 · 2022 · External reference
P1210: immune correlates of response to glofitamab: biomarker findings from a pivotal phase II expansion study in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
10.1097/01.hs9.0000847704.12245.1f · 2022 · External reference
The effect of desensitization protocols on human splenic B-cell populations in vivo
10.1111/j.1600-6143.2006.01632.x · 2007 · External reference
Immunologic effects of rituximab on the human spleen in immune thrombocytopenia
10.1182/blood-2011-03-344051 · 2011 · External reference
Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis
10.1186/ar2789 · 2009 · External reference
Pharmacodynamics of rituximab in kidney allotransplantation
10.1111/j.1600-6143.2006.01497.x · 2006 · External reference
EBV induces CNS homing of B cells attracting inflammatory T cells
10.1038/s41586-025-09378-0 · 2025 · External reference
A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function
10.1111/ajt.12220 · 2013 · External reference
Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy
10.1093/rheumatology/kel148 · 2007 · External reference
Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence
10.1182/blood-2010-02-270678 · 2010 · External reference
A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo
10.1016/j.jim.2017.03.021 · 2017 · External reference
CD141+ dendritic cells produce prominent amounts of IFN-α after dsRNA recognition and can be targeted via DEC-205 in humanized mice
10.1182/blood-2012-12-473413 · 2013 · External reference
Plasmacytoid dendritic cells respond to Epstein-Barr virus infection with a distinct type I interferon subtype profile
10.1182/bloodadvances.2018025536 · 2019 · External reference
Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection
10.1016/j.celrep.2013.11.041 · 2013 · External reference
The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
10.3324/haematol.2019.243543 · 2020 · External reference
Bispecific antibody use in patients with lymphoma and multiple myeloma
10.1200/edbk_433516 · 2024 · External reference
Bispecific antibodies in multiple myeloma: present and future
10.1158/2643-3230.bcd-21-0028 · 2021 · External reference
Epstein-Barr virus transformation of human pre-B cells
10.1084/jem.158.2.616 · 1983 · External reference
Progenitor and pre-B lymphocytes transformed by Epstein-Barr virus
10.1002/ijc.2910390212 · 1987 · External reference
Properties and heterogeneity of human fetal pre-B cells transformed by EBV
10.4049/jimmunol.143.8.2470 · 1989 · External reference
Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging
10.1016/j.cell.2024.04.013 · 2024 · External reference
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
10.1182/blood.2023022432 · 2024 · External reference
CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies
10.1158/1078-0432.ccr-18-0455 · 2018 · External reference
Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions
10.1016/j.jaip.2021.10.037 · 2022 · External reference
Successful blinatumomab treatment in an allogeneic hematopoietic stem cell transplant recipient with EBV-related post-transplant lymphoproliferative disorder: a case report and literature review
10.1016/j.trim.2023.101895 · 2023 · External reference
Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation
10.1182/bloodadvances.2021006535 · 2022 · External reference
